Briquilimab Antibody Delivers Rapid, Lasting Relief in Chronic Urticaria Trials (targeting KIT (CD117)
Jasper Therapeutics announced promising updated clinical data on January 8, 2026, for briquilimab, a monoclonal antibody targeting KIT (CD117) to deplete mast cells and treat mast cell-driven conditions like chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU).
Key highlights include rapid and durable symptom relief, measured by the Urticaria Activity Score over 7 days (UAS7, where 0 indicates complete response):
In additional BEACON participants (240mg loading dose followed by 180mg every 8 week) 83% achieved complete response (UAS7=0) by week 3, and 67% maintained it at week 12.
The dosing is every 2 months.
For CIndU patients, 65% showed complete or partial response at 16 weeks (after the second dose).
The therapy demonstrated a favorable safety profile, with no dose-limiting toxicities.
The data reaffirm briquilimab's potential for rapid, durable control in CSU. This is a new mast cell-targeted approach in addressing unmet needs in chronic urticaria.
Over 20 companies are advancing chronic urticaria trials, with mentions of:
- oral KIT inhibitors
- barzolvolimab (KIT inhibitor) progressing in Phase 3 for CSU and inducible forms like cold urticaria/symptomatic dermographism
- oral MRGPRX2 inhibitors focused on CSU (and potential in asthma, prurigo nodularis)
Chronic Urticaria Treatment Options (click to enlarge the image).